Sarcoma
A092104
Official Title: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
Study Purpose: To compare the progression free survival (PFS) and the overall survival (OS)of olaparib plus temozolomide (Arm 1) as compared to investigator’s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uterine leiomyosarcoma who have received two or more prior lines of therapy as determined by investigator (local site) assessment.
Status:
Suspended